SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: CORRESP
Document Type: CORRESP
Date Filed: 2024-07-29
Accession Number: 0001013762-24-002167
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000101376224002167/filename1.htm

Chunk 1 of 2
Word Count: 455
Character Count: 2856

Document Content:

to access this funding. In this regard, we note that the June 2024 amendment indicates that Knight must approve your operating budget and that Knight is seeking for you to repay $12.4 million from existing loans in the next two years. Response: The Company respectfully acknowledges the Staff’s comment and advises the Staff that it has removed the reference on page 38 of the Amended Registration Statement to reflect that the Company’s ability to access this funding would need to be approved by Knight and is therefore limited. Liquidity, page 38 16. Please expand your disclosures of short- and long-term borrowings to state whether you are in compliance with all of the terms, conditions, and covenants associated with your loan agreements. Response: The Company respectfully acknowledges the Staff’s comment and advises the Staff that it has revised its disclosure on page 40 of the Amended Registration Statement. Management, page 59

17.	We note that Jack Ross is also the CEO of two other entities. Please revise to clarify how he allocates his time across these
three entities.

Response: The Company respectfully acknowledges the Staff’s
comment and advises the Staff that it has revised its disclosure on page 59 of the Amended Registration Statement.

Certain Relationships and Related Party Transactions, page 71

18.	We refer to your disclosure on page 72 concerning your transactions with BoomBod Ltd. Please revise to disclose the nature of
the expenses and reimbursements. With reference to your balance sheet, discuss the timing for repayment of this loan.

Response: The Company respectfully acknowledges the Staff’s
comment and advises the Staff that it has revised its disclosure on page 72 of the Amended Registration Statement.

General

19.	Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act,
that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act,
whether or not they retain copies of the communications.

Response: In response to this comment, we hereby confirm
on behalf of the Company that, as of the date of this letter, no written communications have been presented to potential investors in
reliance on Section 5(d) of the Securities Act. On behalf of the Company, we hereby undertake to provide you with copies of such written
communications to the extent they are generated and used in connection with this offering.

If you have any additional questions regarding
any of our responses or the Amended Registration Statement, please do not hesitate to contact David Mannheim at (919) 329-3804.

Very truly yours,

/s/ W. David Mannheim

W. David Mannheim

cc:	Mike Bradshaw, Nelson Mullins Riley & Scarborough LLP

Jack Ross, Chief Executive Officer, Synergy CHC Corp.